Scripscan:Saamya Biotech (India) Ltd
cmp:3
Code:532905
Story:Incorporated in 2002, Saamya Biotech India Limited (SBIL) is a Hyderabad based Biotech company. SBIL manufactures and market bio pharmaceutical and recombinant protein products to medical and other industries. The company had also entered into a technology transfer agreement with Biofin Laboratories and a sale and purchase agreement with Finchimica, Italy.The company had proposed to set up world class facilities for the manufacture of fermentation based high value Biotech Products. To meet its objective, the company entered the capital market to set up manufacturing facilities including Research & Development and pilot plant facility for Low Volume, High Value active Bio-Pharmaceutical ingredients viz., Daunomycin and Hyaluronic Acid Pharma Grade and Cosmetic Grade. Since its IPO in 2007, a lot has been spoken about its great prospects and bright future but so far till date nothing seems to have materialized.Pathetic numbers too hardly inspires any confidence in the company.At present juncture its a wait and watch bet.
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
